{"url_path":"/sec/bmrn/8-k/2026-04-27/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-04-27","source_url":"https://www.sec.gov/Archives/edgar/data/1048477/0001193125-26-179243-index.html","accession_number":"0001193125-26-179243","cik":"0001048477","ticker":"BMRN","issuer_name":"BIOMARIN PHARMACEUTICAL INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1048477/0001193125-26-179243-index.html","primary_entity_key":"0001048477","primary_entity_name":"BIOMARIN PHARMACEUTICAL INC"},"word_count":423,"has_tables":true,"body_markdown":"8-K\n\nBIOMARIN PHARMACEUTICAL INC false 0001048477 0001048477 2026-04-27 2026-04-27\n\n \n\n \n\nUNITED STATES\n\nSECURITIES AND EXCHANGE COMMISSION\n\nWashington, D.C. 20549\n\n \n\n \n\nFORM 8-K\n\n \n\n \n\nCURRENT REPORT\n\nPursuant to Section 13 OR 15(d)\n\nof The Securities Exchange Act of 1934\n\nDate of Report (Date of earliest event reported): April 27, 2026\n\n \n\n \n\nBioMarin Pharmaceutical Inc.\n\n(Exact name of registrant as specified in its charter)\n\n \n\n \n\n \n\nDelaware\n \n000-26727\n \n68-0397820\n\n(State or other jurisdiction of\n\nincorporation or organization)\n\n \n\n(Commission\n\nFile Number)\n\n \n\n(I.R.S. Employer\n\nIdentification No.)\n\n \n\n770 Lindaro Street\n \nSan Rafael\n \nCalifornia\n  \n94901\n\n(Address of Principal Executive Offices)\n \n\n \n\n  \n(Zip Code)\n\n(415) 506-6700\n\n(Registrant’s telephone number, including area code)\n\nNot Applicable\n\n(Former name or former address, if changed since last report.)\n\n \n\n \n\nCheck the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):\n\n \n\n☐\n\nWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n\n☐\n\nSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n\n☐\n\nPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n\n☐\n\nPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n \n\nTitle of each class\n\n \n\nTrading\nSymbol(s)\n\n \n\nName of each exchange\n\non which registered\n\nCommon Stock, par value $0.001\n \nBMRN\n \nThe Nasdaq Global Select Market\n\nIndicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).\n\nEmerging growth company ☐\n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\n \n\n \n\nIntroductory Note\n\nOn April 27, 2026 (the “Closing Date”), BioMarin Pharmaceutical Inc., a Delaware corporation (“BioMarin” or the “Company”), completed its previously announced merger transaction with Amicus Therapeutics, Inc., a Delaware corporation (“Amicus”), pursuant to that certain Agreement and Plan of Merger (the “Merger Agreement”), dated as of December 19, 2025, by and among BioMarin, Amicus, and Lynx Merger Sub 1, Inc., a Delaware corporation and a wholly owned subsidiary of BioMarin (“Merger Sub”). Pursuant to the terms of the Merger Agreement, Amicus merged with and into Merger Sub (the “Merger”) with Amicus continuing as the surviving corporation and as a wholly owned subsidiary of BioMarin."}